Phase I/IIa Clinical Trials
The Main Reason Clients Choose Cetero …More Than Once.
Early phase clinical research is the heart of our business. That’s what we do best … and do better than anyone else. It’s a matter of having an exceptional array of resources lined up and ready to go: Experienced scientists physicians and clinical teams, outstanding facilities for participants, recruiters experienced with both healthy participants and special patient populations.
It’s a matter of putting together all the studies needed to deliver results as quickly as possible, across multiple therapeutic areas, while always ensuring the safety of our participants:
- First-in-Human: Single and multiple ascending dose in healthy participants or patients
- Proof-of-Concept
- Interaction: Drug-drug, drug-food, and alcohol interaction
- Bioavailability: Absolute bioavailability, bioequivalence
- Pharmacokinetic (PK): Dose proportionality, age/gender, renal or hepatic-impaired
- Pharmacodynamics (PD): Objective or subjective measures performed in-house or with patient diaries
- Thorough QT
Finally, it’s a matter of delivering up to, or exceeding our clients’ high expectations: on time, accurately, safely, with no surprises. That’s what we do, and it’s why our clients have made us the industry’s leading early phase clinical CRO.
Whether you’re a large pharmaceutical company, a small to mid-size biopharmaceutical company or a maker of generic pharmaceuticals, we have what it takes to speed your go/no go decisions so you can move quickly to your next success. Contact us today and tell us about the early phase clinical challenges you’re facing.
